menu ☰
menu ˟

122AUDIT OF ALENDRONATE USE AS FIRST-LINE BISPHOSPHONATE IN PATIENTS ADMITTED TO HOSPITAL WITH FRACTURED NECK OF FEMUR

27 Mar 2018

Evidence-Base: Bone health assessment is fundamental in patients with fragility fracture and forms part of the best practice tariff for hip fracture 1. NICE recommends alendronate for secondary prevention of osteoporotic fragility fractures in postmenopausal women confirmed to have osteoporosis (T-score of −2.5 SD or below) 2. Risedronate can be considered where there is a contraindication or intolerance to alendronate.

Click here to view the full article which appeared in Age and Ageing